Genesis BioPharma is engaged in the development and commercialization of autologous cell therapies for the treatment of various cancers. Genesis’ lead product candidate Cōntego™ is a potential candidate for the treatment of patients with stage IV metastatic melanoma. Cōntego™ is based on the adoptive cell therapy regimen using tumor infiltrating lymphocytes invented by Dr. Steven A. Rosenberg, chief of the Surgery Branch, Center for Cancer Research, National Cancer Institute for the treatment of metastatic melanoma.  For more information visit the company’s Web site at www.genesis-biopharma.com

ROTH Capital Partners is a relationship-driven investment bank that primarily focuses on connecting small-cap publicly traded companies with institutional investors. This year’s annual ROTH conference will take place at The Ritz Carlton located in Dana Point, CA, on March 11-14. Bringing together executives from more than 400 growth companies, the 24th Annual ROTH Conference is one of the largest of its kind in the U.S. For more information on ROTH Capital Partners, visit www.roth.com

Let us hear your thoughts below: